After 24 h treatment, reported PF-04554878 MTS viability IC50 values were 1.98 µM in TT, 23.04 µM in TPC1, 10.34 µM in K1 and >50 µM in BCPAP cells. The variation limits extrapolation of cellular sensitivity across thyroid cancer models. [3]
Time-dependent suppression and recovery of FAK phosphorylation
Cell-based study · HeyA8 and HeyA8-MDR ovarian cancer cells [1]
VS-6063 reduced pFAK Tyr397 during early exposure, with recovery at later time points. This is a cellular phosphorylation endpoint, not an enzyme IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µmol/L
- Exposure duration
- 1, 3, 24 and 48 h
- Method
- Western blot; pFAK Tyr397 intensity relative to total FAK; untreated comparison
- Reported limits
- Vehicle composition was not established from the retrieved main text; linked supplementary DOCX was not retrieved.
Methods and source locations
Compound reported in the paper: Defactinib; Compound label in the paper: VS-6063 (formerly PF-04554878)
Compound-level research findings; no salt conversion or current Adooq lot validation.
Figure 1B and caption; Results: Effect of FAK Inhibition on Sensitivity to PTX; Methods: Western Blot Analysis
FAK Tyr397 phosphorylation relative to total FAK: Triplicate experiments; mean ± standard deviation; caption uses *P < .01 versus untreated. — Figure 1B and caption; Results: Effect of FAK Inhibition on Sensitivity to PTX; Methods: Western Blot Analysis
PYK2-dependent inhibition of IRF5-driven TNF reporter activity
Cell-based study · Wild-type, IRF5-knockout and PYK2-knockout RAW264.7 macrophages, with empty-vector or IRF5-expression controls [2]
Defactinib reduced stimulated TNF reporter activity in wild-type cells and IRF5-deficient cells complemented with IRF5, but not in PYK2-deficient cells. Genetic controls support pathway dependence within this reporter system.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM
- Exposure duration
- 1 h pretreatment followed by 6 h stimulation
- Method
- TNF-luciferase reporter, with unstimulated controls and LPS stimulation (1 µg/mL)
- Vehicle
- DMSO control
- Reported limits
- Salt form and supplier were not established in the read source. No biochemical binding or enzyme potency is inferred.
Methods and source locations
Compound reported in the paper: Defactinib; Compound label in the paper: Defactinib (VS-6063; PF-04554878)
Compound-level research findings; no salt conversion or current Adooq lot validation.
Figure 4a and caption; Results: A PYK2 inhibitor Defactinib interferes with IRF5 activation; Supplementary Figure 5a (PDF page 6)
IRF5-associated TNF-luciferase activity in wild-type and knockout cells: Figure 4a: mean ± SEM, n = 3 independent experiments; two-way ANOVA with Tukey correction. Supplementary Figure 5a checks viability at the selected exposure. — Figure 4a and caption; Results: A PYK2 inhibitor Defactinib interferes with IRF5 activation; Supplementary Figure 5a (PDF page 6)
Model-dependent thyroid cancer cell viability response
Cell-based study · TT, TPC1, K1 and BCPAP thyroid cancer cell lines [3]
Reported PF-04554878 MTS viability responses differed across cell lines. BCPAP did not reach a reported IC50 within 50 µM. These are cellular viability values, not purified FAK inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 1, 5, 10 and 50 µM (Figure 3C)
- Exposure duration
- 24 h
- Method
- MTS viability at 490 nm; zero-dose comparison
- Vehicle
- DMSO stock; final assay percentage not stated in read methods
- Reported limits
- A matched DMSO-only comparison is not explicitly documented in the read assay description; salt/lot specification is not provided.
Methods and source locations
Compound reported in the paper: Defactinib; Compound label in the paper: PF-04554878
Compound-level research findings; no salt conversion or current Adooq lot validation.
Figure 3B right-hand IC50 table and Figure 3C; Results: Y15 inhibited cell viability; Methods: Small molecule inhibitors, Viability, Statistical analysis
TT cellular viability: MTS at 24 h; authors’ fitted values confirmed in viewed Figure 3B table. Each sample analyzed in triplicate; independent experiment count not specified here. — Figure 3B right-hand IC50 table and Figure 3C; Results: Y15 inhibited cell viability; Methods: Small molecule inhibitors, Viability, Statistical analysis
TPC1 cellular viability: MTS at 24 h; authors’ fitted values confirmed in viewed Figure 3B table. Each sample analyzed in triplicate; independent experiment count not specified here. — Figure 3B right-hand IC50 table and Figure 3C; Results: Y15 inhibited cell viability; Methods: Small molecule inhibitors, Viability, Statistical analysis
K1 cellular viability: MTS at 24 h; authors’ fitted values confirmed in viewed Figure 3B table. Each sample analyzed in triplicate; independent experiment count not specified here. — Figure 3B right-hand IC50 table and Figure 3C; Results: Y15 inhibited cell viability; Methods: Small molecule inhibitors, Viability, Statistical analysis
BCPAP cellular viability: MTS at 24 h; authors’ fitted values confirmed in viewed Figure 3B table. Each sample analyzed in triplicate; independent experiment count not specified here. — Figure 3B right-hand IC50 table and Figure 3C; Results: Y15 inhibited cell viability; Methods: Small molecule inhibitors, Viability, Statistical analysis